Ann: $2.5m firm order increases expected DEMECAN revenue to $5.7m, page-14

Now, now guys. Good discussion, lets keep it civil.

I've been comparing various medical marijuana producers based mainly on the relation between cashflow revenue and market cap, revenue and cashflow expenses, plus increases in annual revenue on a rolling basis based on the quaterelys. I've looked at CPH. IHL, LGP and EOF. Just started on ECS, so not able to be too precise, but preliminary notes show that LGP is way ahead of ECS, especially on the Revenue to MC ration - by a long shot. Also, LGP is growing revenue at a great rate; ECS is slow or maybe even going backwards - unable to confirm which yet.